Cargando…

Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations

BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic...

Descripción completa

Detalles Bibliográficos
Autores principales: Remlinger, Jana, Bagnoud, Maud, Meli, Ivo, Massy, Marine, Hoepner, Robert, Linington, Christopher, Chan, Andrew, Bennett, Jeffrey L., Enzmann, Volker, Salmen, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691219/
https://www.ncbi.nlm.nih.gov/pubmed/37429715
http://dx.doi.org/10.1212/NXI.0000000000200141
_version_ 1785152696144101376
author Remlinger, Jana
Bagnoud, Maud
Meli, Ivo
Massy, Marine
Hoepner, Robert
Linington, Christopher
Chan, Andrew
Bennett, Jeffrey L.
Enzmann, Volker
Salmen, Anke
author_facet Remlinger, Jana
Bagnoud, Maud
Meli, Ivo
Massy, Marine
Hoepner, Robert
Linington, Christopher
Chan, Andrew
Bennett, Jeffrey L.
Enzmann, Volker
Salmen, Anke
author_sort Remlinger, Jana
collection PubMed
description BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic nerve demyelination and primary and secondary retinal neurodegeneration are yet to be investigated in animal models. METHODS: Active MOG(35-55) experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6Jrj mice, and monoclonal MOG-IgG (8–18C5, murine), recombinant AQP4-IgG (rAb-53, human), or isotype-matched control IgG (Iso-IgG, human) was administered 10 days postimmunization. Mobility impairment was scored daily. Visual acuity by optomotor reflex and ganglion cell complex thickness (GCC, 3 innermost retinal layers) by optical coherence tomography (OCT) were longitudinally assessed. Histopathology of optic nerve and retina was investigated during presymptomatic, acute, and chronic disease phases for immune cells, demyelination, complement deposition, natural killer (NK) cell, AQP4, and astrocyte involvement, retinal ganglion cells (RGCs), and Müller cell activation. Groups were compared by nonparametric tests with a p value <0.05 indicating statistical significance. RESULTS: Visual acuity decreased from baseline to chronic phase in MOG-IgG (mean ± standard error of the mean: 0.54 ± 0.01 to 0.46 ± 0.02 cycles/degree, p < 0.05) and AQP4-IgG EAE (0.54 ± 0.01 to 0.43 ± 0.02, cycles/degree, p < 0.05). Immune cell infiltration of optic nerves started in presymptomatic AQP4-IgG, but not in MOG-IgG EAE (5.85 ± 2.26 vs 0.13 ± 0.10 macrophages/region of interest [ROI] and 1.88 ± 0.63 vs 0.15 ± 0.06 T cells/ROI, both p < 0.05). Few NK cells, no complement deposition, and stable glial fibrillary acid protein and AQP4 fluorescence intensity characterized all EAE optic nerves. Lower GCC thickness (Spearman correlation coefficient r = −0.44, p < 0.05) and RGC counts (r = −0.47, p < 0.05) correlated with higher mobility impairment. RGCs decreased from presymptomatic to chronic disease phase in MOG-IgG (1,705 ± 51 vs 1,412 ± 45, p < 0.05) and AQP4-IgG EAE (1,758 ± 14 vs 1,526 ± 48, p < 0.01). Müller cell activation was not observed in either model. DISCUSSION: In a multimodal longitudinal characterization of visual outcome in animal models of MOGAD and NMOSD, differential retinal injury and optic nerve involvement were not conclusively clarified. Yet optic nerve inflammation was earlier in AQP4-IgG–associated pathophysiology. Retinal atrophy determined by GCC thickness (OCT) and RGC counts correlating with mobility impairment in the chronic phase of MOG-IgG and AQP4-IgG EAE may serve as a generalizable marker of neurodegeneration.
format Online
Article
Text
id pubmed-10691219
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106912192023-12-02 Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations Remlinger, Jana Bagnoud, Maud Meli, Ivo Massy, Marine Hoepner, Robert Linington, Christopher Chan, Andrew Bennett, Jeffrey L. Enzmann, Volker Salmen, Anke Neurol Neuroimmunol Neuroinflamm Research Article BACKGROUND AND OBJECTIVES: Mechanisms of visual impairment in aquaporin 4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG)–associated disorder (MOGAD) are incompletely understood. The respective impact of optic nerve demyelination and primary and secondary retinal neurodegeneration are yet to be investigated in animal models. METHODS: Active MOG(35-55) experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6Jrj mice, and monoclonal MOG-IgG (8–18C5, murine), recombinant AQP4-IgG (rAb-53, human), or isotype-matched control IgG (Iso-IgG, human) was administered 10 days postimmunization. Mobility impairment was scored daily. Visual acuity by optomotor reflex and ganglion cell complex thickness (GCC, 3 innermost retinal layers) by optical coherence tomography (OCT) were longitudinally assessed. Histopathology of optic nerve and retina was investigated during presymptomatic, acute, and chronic disease phases for immune cells, demyelination, complement deposition, natural killer (NK) cell, AQP4, and astrocyte involvement, retinal ganglion cells (RGCs), and Müller cell activation. Groups were compared by nonparametric tests with a p value <0.05 indicating statistical significance. RESULTS: Visual acuity decreased from baseline to chronic phase in MOG-IgG (mean ± standard error of the mean: 0.54 ± 0.01 to 0.46 ± 0.02 cycles/degree, p < 0.05) and AQP4-IgG EAE (0.54 ± 0.01 to 0.43 ± 0.02, cycles/degree, p < 0.05). Immune cell infiltration of optic nerves started in presymptomatic AQP4-IgG, but not in MOG-IgG EAE (5.85 ± 2.26 vs 0.13 ± 0.10 macrophages/region of interest [ROI] and 1.88 ± 0.63 vs 0.15 ± 0.06 T cells/ROI, both p < 0.05). Few NK cells, no complement deposition, and stable glial fibrillary acid protein and AQP4 fluorescence intensity characterized all EAE optic nerves. Lower GCC thickness (Spearman correlation coefficient r = −0.44, p < 0.05) and RGC counts (r = −0.47, p < 0.05) correlated with higher mobility impairment. RGCs decreased from presymptomatic to chronic disease phase in MOG-IgG (1,705 ± 51 vs 1,412 ± 45, p < 0.05) and AQP4-IgG EAE (1,758 ± 14 vs 1,526 ± 48, p < 0.01). Müller cell activation was not observed in either model. DISCUSSION: In a multimodal longitudinal characterization of visual outcome in animal models of MOGAD and NMOSD, differential retinal injury and optic nerve involvement were not conclusively clarified. Yet optic nerve inflammation was earlier in AQP4-IgG–associated pathophysiology. Retinal atrophy determined by GCC thickness (OCT) and RGC counts correlating with mobility impairment in the chronic phase of MOG-IgG and AQP4-IgG EAE may serve as a generalizable marker of neurodegeneration. Lippincott Williams & Wilkins 2023-07-10 /pmc/articles/PMC10691219/ /pubmed/37429715 http://dx.doi.org/10.1212/NXI.0000000000200141 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Research Article
Remlinger, Jana
Bagnoud, Maud
Meli, Ivo
Massy, Marine
Hoepner, Robert
Linington, Christopher
Chan, Andrew
Bennett, Jeffrey L.
Enzmann, Volker
Salmen, Anke
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title_full Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title_fullStr Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title_full_unstemmed Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title_short Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations
title_sort modeling mog antibody–associated disorder and neuromyelitis optica spectrum disorder in animal models: visual system manifestations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691219/
https://www.ncbi.nlm.nih.gov/pubmed/37429715
http://dx.doi.org/10.1212/NXI.0000000000200141
work_keys_str_mv AT remlingerjana modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT bagnoudmaud modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT meliivo modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT massymarine modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT hoepnerrobert modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT liningtonchristopher modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT chanandrew modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT bennettjeffreyl modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT enzmannvolker modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations
AT salmenanke modelingmogantibodyassociateddisorderandneuromyelitisopticaspectrumdisorderinanimalmodelsvisualsystemmanifestations